Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
This study evaluates blood samples and compares levels of metabolites (levels of vitamins, carbohydrates, proteins, etc., that are in the blood), before and after the plasma exchange in patients scheduled to receive immunotherapy for their ovarian cancer. The information gained from this study may help researchers better understand the side effects from each treatment and possibly lessen those side effects for future treatments.
Full description
PRIMARY OBJECTIVE:
I. To determine the extent to which PARP inhibitor (PARPi) treatment reduces systemic levels of mesenchymal stem cell (MSC)-derived cancer support factors in patients with cancer.
OUTLINE:
Patients undergo collection of blood samples prior to drug initiation, weekly thereafter for the first month of therapy, monthly for the first month, and at disease progression or after cessation of treatment to monitor for toxicity. Blood samples are analyzed. Patients' medical charts are also reviewed to determine outcomes after PARP inhibition.
Enrollment
Sex
Volunteers
Inclusion criteria
- Adults
- Patients with ovarian cancer starting PARP inhibitor treatment
Exclusion criteria
- Patients unwilling to return for blood draws, patients unwilling to continue PARP inhibitor treatment for at least one month
Trial design
5 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal